Blood Stream Infections and Antibiotic Utilization in Pediatric Leukemia Patients with Febrile Neutropenia

James Reinecke, Stefanie Lowas, Jessica Snowden, Kari Neemann

Research output: Contribution to journalArticle

Abstract

Background:Frequent surveillance of bacterial pathogens responsible for microbiologically defined-blood stream infections (MD-BSI), and their respective antibiotic susceptibilities is central to tailoring empiric antibiotic therapy in febrile neutropenia (FN) episodes in pediatric patients with leukemia. The safety of deescalating antibiotic therapy in pediatric patients with leukemia and neutropenia is incompletely understood.Methods:A retrospective chart review of 194 FN episodes occurred between the years of 2013 and 2016 in 67 patients with leukemia. Clinical and microbiologic data were recorded.Results:MD-BSI occurred in 36 of 194 (18%) of FN episodes. Deescalation of empiric antibiotic therapy based on antibiotic susceptibilities was possible in 25 of 36 (69.4%) episodes. In those 25 episodes, where there was an opportunity to deescalate the antibiotic spectrum, it was clinically appropriate to do so in 19. Deescalation occurred in 9 (47.4%) of these episodes without complication. The remaining 10 patients received a median of 20 additional days of broad-spectrum antibiotic therapy (range, 12 to 30 d).Conclusions:In our small cohort of patients, deescalation of antibiotic therapy based on antimicrobial susceptibilities did not result in complication. Larger prospective studies are needed to address the safety of deescalating antibiotic therapy in this population.

Original languageEnglish (US)
Pages (from-to)251-255
Number of pages5
JournalJournal of Pediatric Hematology/Oncology
Volume41
Issue number4
DOIs
StatePublished - May 1 2019

Fingerprint

Febrile Neutropenia
Leukemia
Pediatrics
Anti-Bacterial Agents
Infection
Therapeutics
Safety
Neutropenia
Prospective Studies

Keywords

  • antibiotic stewardship
  • blood stream infections
  • febrile neutropenia
  • leukemia

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Blood Stream Infections and Antibiotic Utilization in Pediatric Leukemia Patients with Febrile Neutropenia. / Reinecke, James; Lowas, Stefanie; Snowden, Jessica; Neemann, Kari.

In: Journal of Pediatric Hematology/Oncology, Vol. 41, No. 4, 01.05.2019, p. 251-255.

Research output: Contribution to journalArticle

@article{8043022fae9c4e859fe8745496fce5a7,
title = "Blood Stream Infections and Antibiotic Utilization in Pediatric Leukemia Patients with Febrile Neutropenia",
abstract = "Background:Frequent surveillance of bacterial pathogens responsible for microbiologically defined-blood stream infections (MD-BSI), and their respective antibiotic susceptibilities is central to tailoring empiric antibiotic therapy in febrile neutropenia (FN) episodes in pediatric patients with leukemia. The safety of deescalating antibiotic therapy in pediatric patients with leukemia and neutropenia is incompletely understood.Methods:A retrospective chart review of 194 FN episodes occurred between the years of 2013 and 2016 in 67 patients with leukemia. Clinical and microbiologic data were recorded.Results:MD-BSI occurred in 36 of 194 (18{\%}) of FN episodes. Deescalation of empiric antibiotic therapy based on antibiotic susceptibilities was possible in 25 of 36 (69.4{\%}) episodes. In those 25 episodes, where there was an opportunity to deescalate the antibiotic spectrum, it was clinically appropriate to do so in 19. Deescalation occurred in 9 (47.4{\%}) of these episodes without complication. The remaining 10 patients received a median of 20 additional days of broad-spectrum antibiotic therapy (range, 12 to 30 d).Conclusions:In our small cohort of patients, deescalation of antibiotic therapy based on antimicrobial susceptibilities did not result in complication. Larger prospective studies are needed to address the safety of deescalating antibiotic therapy in this population.",
keywords = "antibiotic stewardship, blood stream infections, febrile neutropenia, leukemia",
author = "James Reinecke and Stefanie Lowas and Jessica Snowden and Kari Neemann",
year = "2019",
month = "5",
day = "1",
doi = "10.1097/MPH.0000000000001279",
language = "English (US)",
volume = "41",
pages = "251--255",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Blood Stream Infections and Antibiotic Utilization in Pediatric Leukemia Patients with Febrile Neutropenia

AU - Reinecke, James

AU - Lowas, Stefanie

AU - Snowden, Jessica

AU - Neemann, Kari

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Background:Frequent surveillance of bacterial pathogens responsible for microbiologically defined-blood stream infections (MD-BSI), and their respective antibiotic susceptibilities is central to tailoring empiric antibiotic therapy in febrile neutropenia (FN) episodes in pediatric patients with leukemia. The safety of deescalating antibiotic therapy in pediatric patients with leukemia and neutropenia is incompletely understood.Methods:A retrospective chart review of 194 FN episodes occurred between the years of 2013 and 2016 in 67 patients with leukemia. Clinical and microbiologic data were recorded.Results:MD-BSI occurred in 36 of 194 (18%) of FN episodes. Deescalation of empiric antibiotic therapy based on antibiotic susceptibilities was possible in 25 of 36 (69.4%) episodes. In those 25 episodes, where there was an opportunity to deescalate the antibiotic spectrum, it was clinically appropriate to do so in 19. Deescalation occurred in 9 (47.4%) of these episodes without complication. The remaining 10 patients received a median of 20 additional days of broad-spectrum antibiotic therapy (range, 12 to 30 d).Conclusions:In our small cohort of patients, deescalation of antibiotic therapy based on antimicrobial susceptibilities did not result in complication. Larger prospective studies are needed to address the safety of deescalating antibiotic therapy in this population.

AB - Background:Frequent surveillance of bacterial pathogens responsible for microbiologically defined-blood stream infections (MD-BSI), and their respective antibiotic susceptibilities is central to tailoring empiric antibiotic therapy in febrile neutropenia (FN) episodes in pediatric patients with leukemia. The safety of deescalating antibiotic therapy in pediatric patients with leukemia and neutropenia is incompletely understood.Methods:A retrospective chart review of 194 FN episodes occurred between the years of 2013 and 2016 in 67 patients with leukemia. Clinical and microbiologic data were recorded.Results:MD-BSI occurred in 36 of 194 (18%) of FN episodes. Deescalation of empiric antibiotic therapy based on antibiotic susceptibilities was possible in 25 of 36 (69.4%) episodes. In those 25 episodes, where there was an opportunity to deescalate the antibiotic spectrum, it was clinically appropriate to do so in 19. Deescalation occurred in 9 (47.4%) of these episodes without complication. The remaining 10 patients received a median of 20 additional days of broad-spectrum antibiotic therapy (range, 12 to 30 d).Conclusions:In our small cohort of patients, deescalation of antibiotic therapy based on antimicrobial susceptibilities did not result in complication. Larger prospective studies are needed to address the safety of deescalating antibiotic therapy in this population.

KW - antibiotic stewardship

KW - blood stream infections

KW - febrile neutropenia

KW - leukemia

UR - http://www.scopus.com/inward/record.url?scp=85064857194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064857194&partnerID=8YFLogxK

U2 - 10.1097/MPH.0000000000001279

DO - 10.1097/MPH.0000000000001279

M3 - Article

C2 - 30095691

AN - SCOPUS:85064857194

VL - 41

SP - 251

EP - 255

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 4

ER -